InvestorsHub Logo
Followers 827
Posts 119481
Boards Moderated 15
Alias Born 09/05/2002

Re: None

Monday, 03/13/2017 4:36:37 PM

Monday, March 13, 2017 4:36:37 PM

Post# of 178
CHRS had $124.9M cash at 12/31/16—a burn of $34.8M during 4Q16:

http://finance.yahoo.com/news/coherus-biosciences-reports-fourth-quarter-200100429.html

CHRS’ 351(k) application for Neulasta FoB (CHS-1701) has a BsUFA date of 6/9/17.

Today’s PR says CHRS expects to submit a 351(k) application for its Humira FoB (CHS-1420) in 2Q17.

CHRS hasn’t made any claims about its expectations for interchangeable status for any of its FoBs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CHRS News